Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan Market Expansion In Rheumatoid Arthritis Patients Sidelined By PML Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA issues a "complete response" to Genentech/Biogen Idec for sBLA for Rituxan in earlier-stage rheumatoid arthritis.

You may also be interested in...



Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case

Biogen Idec noted that 100,000 patients have been treated with the drug since launch and emphasized that the only reported PML case occurred in a patient on long-term treatment despite having a known risk factor.

Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept

FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.

Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept

FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel